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NEW IMMUNOSUPPRESSIVE AGENTS 
Two-Year Experience With FK 506 in Pediatric Patients 
A.G. Tzakis. J. Reyes, S. Todo, B. Nour, R. Shapiro, M. Jordan, J. McCauley, J. Armitage, J.J. Fung, 
and T.E. Starzl 
THE ENTIRE pediatric experience with FK 506 be-tween September 1989, when the drug was intro-
duced at Children' s Hospital of Pittsburgh, and October 
1991 is presented. Follow-up is to August I. 1992. 
THERAPEUTIC PRINCIPLES 
The starting dose of FK 506 has been kept the same in the 
pediatric population as when the drug was introduced: 0.15 
mglkgld IV as a continuous infusion and 0.15 mglkg bid 
orally. 1 The dose was increased in case of rejection if the 
trough serum FK 506 level was <2 ng/mL and there was 
no nephrotoxicity. The dose was decreased in the absence 
of rejection if the serum FK 506 level was > 3 ng/mL or if 
there was nephrotoxicity. 
The doses. including starting dose. were lower in the 
presence of liver dysfunction. as in liver rescue attempts. 
Prednisone 
Prednisone was administered at 20 mg/d for larger children 
or 10 mg/d for smaller children « 10 kg body weight). It 
was tapered and then discontinued when the graft function 
was stable. In kidney and intestinal transplantation, pred-
nisone starting at 200 mg/d for larger children and 100 mg/d 
for smaller children was used. The dose was tapered to 20 
mg/d and 10 mg/d, respectively, within 5 days. 
Freedom from Steroids 
Of 147 patients who received primary transplantation. and 
are alive with functioning grafts. 126 (86%) are steroid-free 
(93% of liver recipients. 41% of cadaveric kidneys, 71% of 
living related. 82% of heart. 33% of lung, 75% of liver-
intestine. 100% of solitary intestine). Of 57 patients whose 
grafts were successfully rescued. 40 (70%) are steroid-free 
(liver 82%. kidney 20%. heart 100%. lung 100%). 
Azathioprine 
Courses of azathioprine (1 to 2 mg/kg/d) were used as 
supplemental immunosuppression mainly in cases of renal 
impairment. Twelve primary transplant recipients (2 liver. 
I liver intestine. I solitary intestine. 4 kidney, 2 heart. 2 
lung) are receiving azathioprine (1 mgikg/d) long term. In 
the rescue group. only two patients (liver recipients) are 
receiving azathioprine long term. 
OKT3 was used on five occasions for the treatment of 
steroid-resistant rejection. 
Toxicity 
Nephrotoxicity was similar to that observed with cycle-
sporine (CyA).2 No patient required long-term dialysis. 
Five children developed diabetes mellitus which re-
ceded spontaneously in four. 3 One child (liver transplant 
rescue) is receiving insulin long term. 
Five patients developed posttransplantation seizures. 
which were resolved with medical treatment and dose 
reduction if the FK 506 level exceeded 2 ngimL. 
Lymphoproliferative Disease 
Sixteen patients developed this complication4 : 7 primary 
liver recipients. I liver rescue. 2 primary cadaveric kidney 
recipients. I living related kidney recipient. 1 primary 
heart. 1 lung, 1 lung rescue and 2 liver-small bowel 
transplant recipients. 
Thirteen of them are alive and well with the existing 
grafts after dose reduction and acyclovir treatment. Three 
patients died: 1 liver transplant recipient after retransplan-
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Table 1. Two-Year Experience With FK 506 In Pedlatrtc Patients: Primary Transplants 
Kichly Kichly Uver ... Uver-&naJI IsoIaIiId 
Uver' E~I (LAO) He.! Lung Isleta Bowel Small Bowel 
No 116 13 7 21 4 2 6 3 
Age 2 mo-16 y 3-16 Y 8-17 Y 7 h-18 Y 4-15 Y 8 y. 16 Y 6 m0-3y 14 mo-10 y 
Follow-up: 10-34 11-32 11-23 12-33 1()-12 31 13-26 5-9 
(mo) 
Graft SUl'Vl\lal 78% 92% 100% 81% 75% 50% 66'-0 100% 
Patient survival 86% 100% 100% 81% 75% 50% 66% 100% 
'One patient '-* IinUtaneous kidney tranIpIcntation but died from hepa1Ic anary thrombosis. One patient deY8Ioped aplasIIc 8l18iliiii altar transplantation from 
fulminant hepatJUa and u~ SIJCCIISSNI bane rnanow transplantation. 
tation. 1 primary heart. and I liver-small bowel transplant 
recipient. 
Results in Different Groups-Primary Transplantation (Table 
1) 
Liver. One hundred sixteen patients received 128 grafts: 
of those. 100 patients (86%) are alive with normal liver 
function. 1.2 
In six patients. the immunosuppression was completely 
discontinued because of Iymphoproliferative disease (n = 
4), recurrent infection (n = I), or recurrent hepatitis (n = 
I). They remain well with no evidence of rejection 6 to 20 
months after immunosuppression was discontinued. 
Combined Liver-Small Intestine. Six patients with 
combined intestinal and liver failure were treated with a 
combined liver-intestinal transplant. Four are alive with 
normally functioning grafts and no parenteral treatment. 
Two patients died: I of GVHD (a result of reduction of 
immunosuppression to combat peritonitis secondary to an 
anastomotic intestinal leak) and I of lymphoproliferative 
disease.5•6 
Solitary Small Intestine. Three patients received a sol-
itary intestine graft for treatment of intestinal failure. two 
after October 1991, but are included here because of their 
special interest. All patients are alive. well. and free of any 
parenteral therapy. 5.6 
Liver-Pancreatic Islets. Of two patients who received 
liver-pancreatic islets after upper abdominal exenteration 
for extensive malignancy. one died 5 months after trans-
plantation of tumor recurrence.7 The other patient is alive, 
tumor-free. and insulin-free 31 months after transplanta-
tion. This patient represents the first unequivocally suc-
cessful case of islet transplantation. 
Kidney (Cadaveric). Thirteen transplants were per-
formed on 13 patients: 3 were a second and I was a third 
transplant.8 All patients are alive, and all but 2 have 
normally functioning grafts: 1 patient has recurrent mem-
branoproliferative glomerulonephritis and impaired graft 
function, and the second patient lost his graft to recurrent 
hemolytic uremic syndrome. 
Kidney (Living Related Donor). Seven such transplants 
were performed.9 No patient or graft was lost in this group. 
All patients have normally functioning grafts. 
Heart. Twenty-one heart transplants were performed 
with 81% patient and graft survival. Mortalities (n = 4) 
were due to opportunistic infections (n = 3) and Iympho-
proliferative disease (n = 1).10 
Lung. Four patients received double-lung transplanta-
tion either in combination with heart (n = I) or without 
(n = 3). One of these patients died of Aspergillosis. The 
surviving patients have normal graft function. 
Rescue Therapy 
Table 2 refers to rescue attempts to patients with liver. 
kidney. heart. or lung transplants failing under conven-
tional immunosuppression. Of the liver patients. one was a 
liver-heart recipient. The patient required liver transplan-
tation after attempted rescue 1 and died of unsuspected 
heart rejection 9 months later. Three of the patients were 
converted to FK S06 at the time of retransplantation. One 
of them also received a cadaveric kidney transplant at the 
same time. Of the kidney rescue patients. 11 five patients 
had acute rejection. Their rescue attempt was successful. 
Two patients had proteinuria due to chronic rejection and 
lost their grafts. One heart rescue patient died of acute 
rejection 11 months after conversion to FK 506. Initial 
postrescue biopsies showed resolution of the persistent 
acute rejection, which prompted the switch. Poor patient 
compliance or suicide is suspected in this case. IO 
Table 2. Rescue of TranalMnts Treated With Conventlonallmmunoauppreaalon 
Nephrotic SyndrOme. 
Uver KichIy He.! Lung NonIransIlIant 
No 57 7 5 1 9 
Age 9mo-17y IH5y 7-17y lOy 2.5-13 Y 
Follow-up (mo) 11-34 8-26 1G-21 12 10-32 
Graft SUl'Vl\lal 71% 72% 80% 100% 55% Improvec:l 
Patient survival 82% 100% 80% 100% 100% 
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FK 506 PEDIATRIC STUDY 
Chronic GVHD Following Bone Marrow Transplantation 
Five such patients were treated l2: 2 responded to treat-
ment. 1 patient required liver transplantation and is alive 
and well 15 months later. 1 died of pUlmonary failure due 
to GVHD. and the remaining patient has an equivocal 
response. 
Nephrotic Syndrome (Nontransplant) 
Nine patients were treated. ~gK All patients are alive. 5 of 
them (55%) had a favorable response. Advanced renal 
insufficiency or rapidly rising serum creatinine before 
treatment were the most significant prognostic indicators. 
CONCLUSION 
Increasing experience with FK 506 confirms our earlier 
favorable impression of its use in pediatric patients. It can 
be used virtually without steroids in the treatment of 
recipients of conventional transplants. It is efficacious in 
salvaging patients who failed conventional immunosup-
pression. It allows successful transplantation of previously 
forbidden organs. such as intestine and pancreatic islets. It 
can be effective in the treatment of nephrotic syndrome. 
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